Parathyroid Tumor Biology and Clinical Management

Parathyroid tumours encompass a spectrum from benign adenomas to rare carcinomas, all arising from chief cells that regulate calcium homeostasis via parathyroid hormone (PTH) secretion. At a molecular level, disruption of tumour suppressors—most notably CDC73, which encodes the nuclear protein parafibromin—underlies hereditary syndromes and many sporadic carcinomas. Adenomas typically harbour cyclin-related abnormalities and localised overexpression of proliferative signals, whereas carcinomas often exhibit biallelic inactivation of CDC73, activation of cell-cycle drivers such as CCND1, and aberrant signalling through pathways including PI3K/AKT/mTOR and WNT/β-catenin. The tumour microenvironment, marked by inflammatory infiltrates and fibroblast activation, further contributes to growth and progression.

Clinically, primary hyperparathyroidism presents with hypercalcaemia, nephrolithiasis, bone disease and neuropsychiatric symptoms. Biochemical screening with PTH and corrected calcium measurements guides diagnosis, while localisation relies on ultrasonography and sestamibi scanning. Surgical parathyroidectomy remains the cornerstone of treatment, with en bloc resection required for carcinoma and minimally invasive approaches reserved for solitary adenomas. Genetic testing is recommended for early-onset disease, multigland involvement or a positive family history, informing both surgical planning and familial surveillance. Postoperative monitoring focuses on calcium homeostasis and recurrence, while medical therapies for inoperable carcinoma remain investigational.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Parathyroid Tumor Biology and Clinical Management publication trend

The graph below shows the total number of articles in parathyroid tumor biology and clinical management across all publications each year (not limited to Nature Index journals).

Technical terms

Primary hyperparathyroidism: A condition of excessive parathyroid hormone secretion leading to hypercalcaemia and related complications.

Parathyroid adenoma: A benign neoplasm of parathyroid chief cells causing overproduction of parathyroid hormone.

Parathyroid carcinoma: A malignant tumour of the parathyroid gland characterised by invasive growth, potential metastasis and severe hypercalcaemia.

CDC73: A tumour suppressor gene encoding parafibromin, frequently inactivated in hereditary and sporadic parathyroid carcinomas.

Parafibromin: The nuclear protein product of CDC73 that regulates transcription and cell-cycle control.

Transcriptomic profiling: Genome-wide analysis of RNA expression patterns to characterise cellular states and disease-specific signatures.

References

1. Molecular and Clinical Spectrum of Primary Hyperparathyroidism. Endocrine Reviews (2023).
2. Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma. Experimental & Molecular Medicine (2023).
3. KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma. Clinical and Translational Medicine (2024).